Lucid Diagnostics Stock Forum

$Lucid Diagnostics (LUCD.US)$ Reuters· 3 mins ago
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its Esoguard Esophageal DNA Test

$Lucid Diagnostics (LUCD.US)$ Lucid Diagnostics Signs Memorandum of Understanding With Front Line Mobile Health
PR Newswire· 4 mins ago
Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters

$Lucid Diagnostics (LUCD.US)$ Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard for Early Detection of Esophageal Precancer and Cancer
PR Newswire· 5 mins ago
Study demonstrates excellent analytical accuracy, repeatability, and reproducibility of the assay

$Lucid Diagnostics (LUCD.US)$ Lucid Diagnostics Announces Positive Data From Envet-Be Clinical Utility Study of Esoguard® Esophageal Precancer Testing

$Lucid Diagnostics (LUCD.US)$ Reuters · 1 min ago                                       Lucid Diagnostics Announces Positive Data From Its Esoguard Be-1 Prospective, International, Multicenter Clinical Validation Study of Esoguard® Esophageal Precancer Testing in a Screening Population

$Lucid Diagnostics (LUCD.US)$ Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data From National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing
PR Newswire· 2 mins ago

$Lucid Diagnostics (LUCD.US)$
NEWS
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
The peer-reviewed publication of positive data from a National Cancer Institute-sponsored study enhances Lucid Diagnostics' reputation and credibility in the medical diagnostics field.
EsoGuard's demonstration of unprecedented early precancer detection with 89...

$Lucid Diagnostics (LUCD.US)$ Lucid Diagnostics posted Q4 revenues of $1 million, marking a 33% increase from Q3 and a 829% increase annually.
Non-GAAP net loss for the quarter was $9.9 million, showing a slight increase from Q3 but a year-over-year decrease of $700,000.
The company had a year-end cash balance of $18.9 million, supported by a recent financing of $18.1 million.
Approximately 50% of the claims submitted have been adjudicated, with an averaging payment of $1,800.
The projected re...

$Lucid Diagnostics (LUCD.US)$ Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
PR Newswire· 1 min ago
The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants at almost 2.5K per billable test